je.st
news
Tag: investigational
Phase III data show investigational compound empagliflozin...
2013-06-22 19:08:23| Biotech - Topix.net
In the pooled analysis, presented at the American Diabetes Association 73rd Scientific SessionsA , people with T2D treated with empagliflozin versus placebo achieved significant reductions in HbA1c, fasting plasma glucose , weight and blood pressure after 24 weeks.1 In the same analysis, people treated with empagliflozin vs. placebo experienced an ... (more)
Merck Announces Presentation of Interim Data from Study Evaluating Lambrolizumab, an Investigational Anti-PD-1 Antibody, in Patients with Advanced Melanoma at ASCO 2013
2013-06-02 17:15:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. -Merck Expands Lambrolizumab Clinical Development Program- -Study Published Online in the New England Journal of Medicine- WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of preliminary results from an ongoing Phase IB expansion study evaluating the safety and efficacy of lambrolizumab (MK-3475), Mercks investigational antibody therapy targeting PD-1, in patients with advanced (inoperable and metastatic) melanoma. Language: English Contact HTML: MerckMedia Contacts:Ian McConnell, 973-901-5722Cathy Cantone, 908-327-3013orInvestor Contacts:Carol Ferguson, 908-500-1101Justin Holko, 609-915-8293 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
advanced
study
presentation
Merck Provides Update on Phase III Clinical Program for Preladenant, the Companys Investigational Parkinsons Disease Medicine
2013-05-23 23:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today provided an update on the clinical program for preladenant, Mercks investigational adenosine A2A receptor antagonist for the treatment of Parkinsons disease (PD). An initial review of data from three separate Phase III trials did not provide evidence of efficacy for preladenant compared with placebo. Language: English Contact HTML: MerckMedia Contacts:Pam Eisele, 908-423-5042orClaire Mulhearn, 908-423-7425orInvestor Contacts:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: program
iii
update
medicine
Merck Announces FDA Acceptance of Biologics License Application for Investigational Ragweed Pollen Sublingual Allergy Immunotherapy Tablet
2013-05-08 14:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Biologics License Application (BLA) for its investigational ragweed pollen (Ambrosia artemisiifolia) sublingual allergy immunotherapy tablet has been accepted for review by the U.S. Food and Drug Administration (FDA). On March 27, Merck announced that the FDA had also accepted the BLA for its investigational Timothy grass pollen (Phleum pratense) sublingual allergy immunotherapy tablet. Language: English Contact HTML: MerckMedia:Pam Eisele, 908-423-5042Robert Consalvo, 908-423-6595orInvestor:Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: application
license
acceptance
announces
Merck, Pfizer partner on investigational diabetes drug
2013-04-29 23:28:36| Biotech - Topix.net
Merck & Co. Inc. and Pfizer Inc. have agreed to collaborate on the development of a combination drug for type 2 diabetes.
Tags: partner
drug
diabetes
merck
Sites : [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] next »